VivoSeq
Infectious Disease

Human African Trypanosomiasis

6

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Human African Trypanosomiasis is an early-stage landscape with 6 programs across 2 companies. The most active players are Bayer, Sanofi. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

77/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

14

clinical trials

Completed10 · 71%
Terminated3 · 21%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)
Not yet recruiting·DDrugs for Neglected Diseases·Phase 3·NCT06356974·2,500 enrolled
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole
Completed·DDrugs for Neglected Diseases·Phase 1·NCT00982904·108 enrolled
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Completed·DDrugs for Neglected Diseases·Phase 3·NCT03025789·174 enrolled
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
Completed·DDrugs for Neglected Diseases·Phase 3·NCT00146627·280 enrolled
Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
Completed·DDrugs for Neglected Diseases·Phase 4·NCT00906880·630 enrolled
Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study
Completed·DDrugs for Neglected Diseases·Phase 2/3·NCT02184689·125 enrolled
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
Completed·DDrugs for Neglected Diseases·Phase 2/3·NCT01685827·394 enrolled
Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense
Completed·DDrugs for Neglected Diseases·Phase 2/3·NCT03974178·45 enrolled
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
Completed·DDrugs for Neglected Diseases·Phase 1·NCT01533961·136 enrolled
Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
Completed·DDrugs for Neglected Diseases·Phase 2/3·NCT03087955·208 enrolled
Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study
Completed·DDrugs for Neglected Diseases·Phase 2/3·NCT02169557·230 enrolled
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
Terminated·DDrugs for Neglected Diseases·Phase 1·NCT01483170·30 enrolled
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
Terminated·EEpicentre·Phase 3·NCT00330148·435 enrolled
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
Terminated·EEpicentre·Phase 2/3·NCT00489658·31 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)